Prevalence of Inhibitors to Factor VIII After 25 Exposures to Factor VIII Concentrates and/or Blood Products in Persons With Hemophilia A

Journal of Medical Science And Clinical Research
doi 10.18535/jmscr/v5i10.14
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Valley International

Related search

Highly Purified Porcine Factor VIII in Haemophilia a With Inhibitors to Factor VIII

BMJ
1981English

The Impact of Factor VIII/von Willebrand Factor Products in Inhibitor Development and Management of Patients With Hemophilia a With Inhibitors

Oncology & Hematology Review (US)
2007English

Reactions to Low-Molecular-Weight Porcine Factor VIII Concentrates.

BMJ
1981English

Postpartum Acquired Hemophilia Factor VIII �nhibitors and Response to Therapy

Turkish Journal of Haematology
Hematology
2012English

Factor VIII Associated With Lipidic Nanoparticles Retains Efficacy in the Presence of Anti-Factor VIII Antibodies in Hemophilia a Mice

Biopharmaceutics and Drug Disposition
MedicinePharmacologyPharmaceutical Science
2016English

Long-Term Expression of Human Coagulation Factor VIII and Correction of Hemophilia a After in Vivo Retroviral Gene Transfer in Factor VIII-deficient Mice

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1999English

Survival of 125iodine-Labeled Factor VIII in Normals and Patients With Classic Hemophilia. Observations on the Heterogeneity of Human Factor VIII.

Journal of Clinical Investigation
Medicine
1978English

Improving the Performance of Factor VIII Inhibitor Tests in Hemophilia A

Thrombosis Research
Hematology
2015English

244. Factor VIII Immunogenicity Is a Barrier to AAV Gene Therapy for Hemophilia A

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy